Biocon Biologics’ partner receives positive EU CHMP opinion for biosimilar human insulin for IV infusion
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
Approval is based on results of a multicenter, randomized, open-labeled and controlled IDE clinical study that demonstrated the superiority of Agili-C™ implant to the current surgical standard of care, debridement and microfracture in the knee joint
AbbVie to present 30 abstracts demonstrating its leadership in neuroscience, including continued migraine treatment research across the spectrum of the disease, commitment to patients with advanced Parkinson's disease, and new studies in spasticity and cervical dystonia
Launched in the year 2018, MedEngage Scholarship Program is aimed at nurturing and nourishing medical talent in India
This targeted capacity-building and advocacy project in 15 districts and 5 states of India has facilitated the certification of disability for 11,152 people, provided disability pensions to 8,144 people and supported the issuing of voter IDs to 8,450 people with disabilities
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
The survey indicates that 30% of people are still feeling depressed or hopeless on a few days as against GOQii’s last year survey on mental Health where 43% of Indians were depressed
New data, including two late-breaking clinical trial presentations on mavacamten and a new analysis of the GUARD-AF study, reinforce the company’s continued commitment to those living with cardiovascular disease
Twelve abstracts and two late-breaking presentations demonstrate AbbVie and Allergan Aesthetics' shared commitment to advancing research across a spectrum of dermatologic conditions and aesthetic indications
Manipal Hospitals partners with ConnectedLife, leveraging Fitbit wearable technology, for Continuity of Care Post-High-Risk Surgeries built with Google Cloud
Subscribe To Our Newsletter & Stay Updated